News
This marks the first and only FDA-approved medicine for low-grade serous ovarian cancer (LGSOC) that tests positive for a gene change known as the KRAS mutation. The treatment includes two drugs ...
Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.
May 9 (UPI) --The U.S. Food and Drug Administration on Friday approved Teal Health to provide the nation's first at-home test kit to screen for cervical cancer. The Teal Wand, which will be ...
In an effort to combat the prevalence of cervical cancer in the United States, the Food and Drug Administration has approved the first ever at-home cervical cancer screening kit. On Friday ...
Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...
The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results